

Definitions for LSSS quarterly returns

Part 1F: Number of people setting a quit date and successful quitters by pharmacotherapy treatment received

51	Number who received a single licensed nicotine containing product (NRT) only	<i>Total number of people using only one form of NRT at a time, at any one point during their quit attempt.</i>
52	Number who received a combination of licensed nicotine containing products (NRTs) concurrently	<i>Total number of people using two or more forms of NRT at the same time at any time during their quit attempt.</i>
53	Number who received bupropion (Zyban) only	<i>Total number of people using bupropion (Zyban) only during their quit attempt.</i>
54	Number who received varenicline (Champix) only	<i>Number who received varenicline (Champix) only during their quit attempt.</i>
55	Number who received a licensed nicotine containing product (NRT), and/or bupropion (Zyban) and/or Champix (Varenicline) consecutively	<i>Total number of people who switched between any or all of the following during a single quit attempt but did not use them at the same time: NRT, varenicline (Champix), bupropion (Zyban).</i>
56	Number who used a combination of a licensed medication and an unlicensed nicotine containing product concurrently	<i>Total number of people who used a licensed medication (NRT, varenicline (Champix) or bupropion (Zyban)) at the same time as an unlicensed nicotine containing product (such as unlicensed electronic cigarettes) at any time during their quit attempt.</i>
57	Number who used a licensed medication and an unlicensed nicotine containing product consecutively	<i>Total number of people who started using either a licensed medication (NRT, varenicline (Champix) or bupropion (Zyban)) or an unlicensed nicotine containing product (such as unlicensed electronic cigarettes) and then switched to the other during a single quit attempt and did not use them at the same time.</i>
58	Number who used an unlicensed nicotine containing product only	<i>Total number of people who only used unlicensed nicotine containing products (such as unlicensed electronic cigarettes) and no licensed medication during their quit attempt.</i>
59	Number who did not use any licensed medication or unlicensed nicotine containing product	<i>Total number of people who did not receive or use any form of stop smoking medication or unlicensed nicotine containing product (such as unlicensed electronic cigarettes) at any point during their quit attempt.</i>
60	Number where treatment option not known	<i>Total number of people where a treatment option was not recorded during their quit attempt.</i>

The term **licensed nicotine containing product** has been used to cover any product containing nicotine that has received a license from the MHRA for use as an aid to cessation. This applies to all products currently defined as nicotine replacement therapies (NRTs) and will apply to any nicotine containing products which receive licences from the MHRA during the course of this and future collections, such as may happen with an electronic cigarette type device.

The term **unlicensed nicotine containing product** has been used to cover any product containing nicotine that has not received a license from the MHRA for use as an aid to cessation. It is expected that this term will mainly cover the use of unlicensed electronic cigarettes.

The term **licensed medication** has been used to apply to any medicine that has received a license from the MHRA and includes NRT, varenicline and bupropion.

Part 1H: Number of people setting a quit date and successful quitters by intervention setting

Please note that the setting recorded should be the setting where the majority of care has been provided and not the setting in which the treatment was initiated.

72	Community setting	<i>Any community setting that is not described by any of the options below including where the intervention is delivered in the client's own home.</i>
73	Community psychiatric setting	<i>Any primary care psychiatric setting that is not described by any of the options below including where the intervention is delivered in the client's own home.</i>
74	Hospital setting	<i>Any treatment delivered in a secondary care setting, be this inpatient, outpatient, ward or clinic.</i>
75	Psychiatric hospital setting	<i>Any treatment delivered in a psychiatric secondary care setting, be this inpatient, outpatient, ward or clinic.</i>
76	Pharmacy setting	<i>Any treatment delivered from a pharmacy setting.</i>
77	Dental setting	<i>Any treatment delivered from a dental setting.</i>
78	General practice setting	<i>Any treatment delivered from a general practice setting.</i>
79	Maternity setting	<i>Any treatment delivered in a maternity setting.</i>
80	Children's centre setting	<i>Any treatment delivered in a children's centre setting.</i>
81	School setting	<i>Any treatment delivered in a school setting.</i>
82	Prison setting	<i>Any treatment delivered in a prison setting.</i>
83	Military base setting	<i>Any treatment delivered on a military base.</i>
84	Workplace setting	<i>Any treatment delivered in a workplace setting.</i>
85	Other	<i>Any treatment delivered in a setting not described by any of the above. Please describe in the comments box.</i>

This part of the data collection is to record the setting in which an intervention has taken place. This is used to understand where interventions are taking place and to provide understanding of the demographics of the populations which attend services in these settings.

It should not be used as a proxy to record the staff group that provide interventions in these settings, i.e. community for core local stop smoking service staff, pharmacy as a proxy for pharmacy staff, general practice for general practice staff and maternity for maternity staff.

Where that information is required, it should be extracted from the database using the identifier for those staff groups. As an example for general practice staff; extracting all activity reported by services delivered in general practice, where the person delivering the service is employed by the practice, and not a member of core LSSS staff providing a service in that setting.

There is limited value in using this data as a proxy for activity within certain staff groups as this does not capture the variance between staff groups in these settings and cannot reliably be used to manage performance in these settings.

Where this section has historically been used to record staff group, please do not change your recording methods this year (2015/16) rather we request that the data collected from April 2016 onwards follows this latest definition.

Change can be made as per the definitions for Part 1F and Part 2 for the Quarter 3 2015/16 collection as well as the opportunity to refresh Quarter 1 and Quarter 2.

If your data for Part 1H is recorded by staff group rather than intervention setting, please continue to do so for the rest of the reporting year. From Quarter 1 2016/17 please record as per the definitions provided.

From the feedback received following the change to this data collection last year we recognise that there is still a large variance in the costs included in this section. We recognise that the request for information has not been made sufficiently clear as to ensure consistency of reporting between services.

We are considering changes to the way that this data will be requested in the future to provide further clarity and will provide details of these in due course. Until that point please report data following the definitions below. Where there is still a lack of clarity or should you have further questions, please direct enquiries to:

data.collections@hscic.gov.uk

Part 2: Summary financial information on smoking cessation services

Part 2A: Financial allocations for year

89	<p>LA allocation for smoking cessation for year (excluding pharmacotherapies)</p>	<p>This is the total funding allocated to the delivery of stop smoking services for the full year.</p> <p>It includes monies allocated to cover the salaries of staff employed to deliver stop smoking services including staff training, continuing professional development and other activities to increase the quality of the service.</p> <p>It includes any money allocated for the delivery of quits, including those which are delivered by subcontracted providers where these are reported through this data collection, for example SLAs with GPs or pharmacies.</p> <p>It includes monies allocated to wider tobacco control, where the intended purpose is to increase attendance at stop smoking services.</p> <p>It does not include the cost of pharmacotherapy.</p> <p>It does not include monies allocated to activities such as trading standards or enforcement activities where this is not directly intended to increase attendance at stop smoking services.</p> <p>This figure is entered at the start of the year and as it is the total allocation for the year should not change from quarter to quarter.</p>
90	<p>Total cost of pharmacotherapies issued as part of this service for the year.</p> <p>If you cannot accurately report this information and feel confident to provide an accurate estimate for this total then please do, noting that this is an estimate in the comments box.</p> <p>If you cannot provide accurate information and feel unable to provide an sufficiently accurate estimation then please enter a zero and provide any comments in the comments box.</p>	<p>This is the total cost of pharmacotherapies issued as part of the stop smoking service for the year to date.</p> <p>It does not include pharmacotherapies issued that are not part of a planned stop smoking service 4 week quit intervention, such as a clinician who is not reporting activity through this data return, (e.g. a GP providing medication alone as part of their standard primary care offer, not referring to or including the SSS), or any harm reduction activity that does not result in the client setting a quit date.</p> <p>It is a cumulative figure and as such should increase each quarter, with the figure for Q4 being the total spend for the full year.</p>

91	Other additional costs attributable to delivery of smoking cessation services, including any underspend carried over from the previous year.	<p>This is any other funding allocated to projects where the intended purpose is to increase attendance at stop smoking services.</p> <p>This includes any in-year spend that was not initially allocated and recorded in row 89 and is directly intended to increase attendance at stop smoking services.</p> <p>This includes any activity that has been delivered by non-local authority providers, such as NHS E commissioned services in prisons or hospitals, where this data is being reported as part of the local authority return.</p> <p>It is a cumulative figure and as such should increase each quarter, with the figure for Q4 being the total spend for the full year.</p>
----	--	---

Part 2B: Cumulative total spend on smoking cessation services in the year up to the end of the quarter (£)

93	Cumulative spend	<p>This is the actual spend covering the delivery of stop smoking services for the year to date. It does include the cost of pharmacotherapy and monies allocated to wider tobacco control, where the intended purpose is to increase attendance at stop smoking services, whether these be allocated at the start of the year, or added to the budget in year. It is a cumulative figure and as such should increase each quarter, with the figure for Q4 being the total spend for the full year.</p>
----	------------------	---